Angiogenesis - Cell Experiments
Angiogenesis is the growth of new blood vessels from the existing vasculature. This process is involved in development, wound healing, embryo formation and tumor growth. Activation of angiogenesis leads to the release of pro-angiogenic growth factors such as VEGF, PDGF, FGF and TGF, which bind their receptors on endothelial cells within pre-existing vessels. As a result, it induces signal transduction of various pathways such as PI3K/Akt, Erk1/2, Smad and Notch, causing endothelial cells proliferation and migration. Endothelial cells use matrix metalloproteases and integrins to digest extracellular matrix and migrate into new area, where they lengthen and form tubes, generating new blood vessel.
During tumor angiogenesis, cancer cells stimulate formation of new blood vessel for delivering oxygen and nutrients to a tumor. As the tumor grows, cells at the center of the mass become starved of oxygen, causing hypoxia. It stabilizes the expression of a transcription factor, HIF-1α (hypoxia inducible factor-1), which binds HIF-1β to upregulate the expression of several angiogenesis-promoting genes. Moreover, growth factor signaling also stimulates HIF-1 activity in order to maintain oxygen homeostasis for growing cells.
清除全部
- B1115 BAY 87-2243Target: Hypoxia Inducible Factors (HIFs)Summary: 有效的HIF-1选择性抑制剂
- B2298 Plinabulin (NPI-2358)中文名: 普那布林Target: Vascular Disrupting Agents (VDA)Summary: 血管破坏剂
- A8675 TRAP-6中文名: 凝血酶受体激活肽6Target: PARSummary: PAR1激动剂
- A8669 AC 55541Target: PARSummary: PAR2激动剂
- A8233 DMXAA (Vadimezan)2 Citation中文名: 2,5-己酮可可碱Target: DT-diaphorasesSummary: 肿瘤血管破坏剂,细胞凋亡诱导剂。
- A8229 ML161Target: Protease-Activated ReceptorsSummary: PAR1抑制剂
- A4509 PX 12Target: TrxSummary: Trx-1抑制剂